Related Experiment Video
Updated: Jun 6, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon
1ChipDX LLC, PO Box 286874, New York, NY 10128, USA. ryan.vanlaar@chipdx.com
Background:
the decision whether to treat patients with non-metastatic colon cancer with adjuvant chemotherapy is determined by clinical staging, frequently resulting in over or undertreatment.
Methods:
gene expression data and clinical information from 232 stage 1-4 colon cancer patients were analysed to identify expression patterns predictive of recurrence. The signature was evaluated on an independent series of 60 stage 2 and 3 patients. Multivariate analyses were performed to assess the clinical utility of the assay.
Results:
a 163-probe signature was able to stratify patients into high- and low-risk groups for disease-free survival (DFS) in both the training and validation series (stage 2: P0.031, stage 3: P0.057) and for disease-specific survival in the training series (stage 2: P=0.01, stage 3: P=0.0017). Multivariate analysis showed the classifier to be associated with approximately three- to fourfold increased risk of recurrence.
Conclusions:
the prognostic gene expression signature is able to stratify stage 2 and 3 colon cancer patients into groups with significant differences in 5-year DFS, information that may ultimately reduce deaths from colon cancer. Further validation work is required and at this stage the assay is available for evaluation at www.ChipDX.com.
